Checkpoint Capital L.P. Buys 10,350 Shares of argenx SE (NASDAQ:ARGX)

Checkpoint Capital L.P. boosted its position in argenx SE (NASDAQ:ARGX) by 12.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 92,500 shares of the company’s stock after purchasing an additional 10,350 shares during the period. argenx makes up about 24.9% of Checkpoint Capital L.P.’s portfolio, making the stock its largest holding. Checkpoint Capital L.P. owned 0.15% of argenx worth $50,142,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after purchasing an additional 1,265,486 shares during the last quarter. Perpetual Ltd bought a new stake in argenx during the third quarter worth approximately $76,314,000. Logos Global Management LP acquired a new position in argenx in the second quarter worth approximately $58,055,000. Sei Investments Co. increased its holdings in shares of argenx by 15.2% in the second quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock valued at $164,079,000 after buying an additional 50,477 shares in the last quarter. Finally, Tri Locum Partners LP lifted its position in shares of argenx by 166.5% during the 2nd quarter. Tri Locum Partners LP now owns 74,558 shares of the company’s stock valued at $32,063,000 after acquiring an additional 46,577 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Trading Up 0.3 %

Shares of NASDAQ:ARGX opened at $616.55 on Monday. The stock has a market capitalization of $37.22 billion, a PE ratio of -700.63 and a beta of 0.61. argenx SE has a 1 year low of $327.73 and a 1 year high of $620.28. The firm has a fifty day moving average price of $565.73 and a 200 day moving average price of $498.07.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. During the same quarter in the prior year, the company posted ($1.25) EPS. On average, sell-side analysts forecast that argenx SE will post 2.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ARGX. Barclays upgraded argenx from an “equal weight” rating to an “overweight” rating in a report on Tuesday, August 6th. Baird R W cut argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Evercore ISI boosted their price objective on argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Robert W. Baird cut shares of argenx from an “outperform” rating to a “neutral” rating and raised their target price for the stock from $515.00 to $650.00 in a report on Friday, November 1st. Finally, Piper Sandler boosted their price target on shares of argenx from $553.00 to $620.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $630.42.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.